Histone Deacetylase Inhibitors Down-Regulate bcl-2 Expression and Induce Apoptosis in t(14;18) Lymphomas

REFERENCES

• Alland, L., R. Muhle, H. J. Hou, J. Potes, L. Chin, N. Schreiber-Agus, and R. A. DePinho. 1997. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387:49–55.
   PubMed Web of Science ®Google Scholar
• Barlev, N. A., L. Liu, N. H. Chehab, K. Mansfield, K. G. Harris, T. D. Halazonetis, and S. L. Berger. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8:1243–1254.
   PubMed Web of Science ®Google Scholar
• Bennett, M. K., T. T. Ngo, J. N. Athanikar, J. M. Rosenfeld, and T. F. Osborne. 1999. Costimulation of promoter for low density lipoprotein receptor gene by sterol regulatory element-binding protein and Sp1 is specifically disrupted by the yin yang 1 protein. J. Biol. Chem. 274:13025–13032.
   PubMedGoogle Scholar
• Berger, S. L. 2002. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 12:142–148.
   PubMed Web of Science ®Google Scholar
• Braun, H., R. Koop, A. Ertmer, S. Nacht, and G. Suske. 2001. Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res. 29:4994–5000.
   PubMed Web of Science ®Google Scholar
• Brownell, J. E., J. Zhou, T. Ranalli, R. Kobayashi, D. G. Edmondson, S. Y. Roth, and C. D. Allis. 1996. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 84:843–851.
   PubMed Web of Science ®Google Scholar
• Chen, C., and B. K. Birshtein. 1997. Virtually identical enhancers containing a segment of homology to murine 3′ IgH-E(hs1,2) lie downstream of human Ig Cα1 and Cα2 genes. J. Immunol. 159:1310–1318.
   PubMedGoogle Scholar
• Christenson, L. K., R. L. Stouffer, and J. F. Strauss III. 2001. Quantitative analysis of the hormone-induced hyperacetylation of histone H3 associated with the steroidogenic acute regulatory protein gene promoter. J. Biol. Chem. 276:27392–27399.
   PubMed Web of Science ®Google Scholar
• Cleary, M. L., S. D. Smith, and J. Sklar. 1986. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47:19–28.
   PubMed Web of Science ®Google Scholar
• Dehm, S. M., T. L. Hilton, E. H. Wang, and K. Bonham. 2004. SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors. Mol. Cell. Biol. 24:2296–2307.
   PubMedGoogle Scholar
• Desilets, A., I. Gheorghiu, S. J. Yu, E. G. Seidman, and C. Asselin. 2000. Inhibition by deacetylase inhibitors of IL-1-dependent induction of haptoglobin involves CCAAT/enhancer-binding protein isoforms in intestinal epithelial cells. Biochem. Biophys. Res. Commun. 276:673–679.
   PubMedGoogle Scholar
• Desoize, B. 1994. Anticancer drug resistance and inhibition of apoptosis. Anticancer Res. 14:2291–2294.
   PubMed Web of Science ®Google Scholar
• Epstein, A. L., R. Levy, H. Kim, W. Henle, G. Henle, and H. S. Kaplan. 1978. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer 42:2379–2391.
   Google Scholar
• Ferguson, M., P. A. Henry, and R. A. Currie. 2003. Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. Nucleic Acids Res. 31:3123–3133.
   PubMed Web of Science ®Google Scholar
• Graninger, W. B., M. Seto, B. Boutain, P. Goldman, and S. J. Korsmeyer. 1987. Expression of bcl-2 and bcl-2-Ig fusion transcripts in normal and neoplastic cells. J. Clin. Investig. 80:1512–1515.
   PubMed Web of Science ®Google Scholar
• Gregory, P. D., K. Wagner, and W. Horz. 2001. Histone acetylation and chromatin remodeling. Exp. Cell Res. 265:195–202.
   PubMed Web of Science ®Google Scholar
• Grunstein, M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389:349–352.
   PubMed Web of Science ®Google Scholar
• Gui, C.-Y., L. Ngo, W. S. Xu, V. M. Richon, and P. A. Marks. 2004. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101:1241–1246.
   PubMed Web of Science ®Google Scholar
• Heckman, C., E. Mochon, M. Arcinas, and L. M. Boxer. 1997. The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas. J. Biol. Chem. 272:19609–19614.
   PubMedGoogle Scholar
• Heckman, C. A., T. Cao, L. Somsouk, H. Duan, J. W. Mehew, C. Zhang, and L. M. Boxer. 2003. Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res. 63:6666–6673.
   PubMedGoogle Scholar
• Heckman, C. A., J. W. Mehew, and L. M. Boxer. 2002. NF-κB activates bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21:3898–3908.
   PubMed Web of Science ®Google Scholar
• Heckman, C. A., J. W. Mehew, G.-G. Ying, M. Introna, J. Golay, and L. M. Boxer. 2000. A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J. Biol. Chem. 275:6499–6508.
   PubMedGoogle Scholar
• Heckman, C. A., M. A. Wheeler, and L. M. Boxer. 2003. Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 22:7891–7899.
   PubMed Web of Science ®Google Scholar
• Henderson, C., M. Mizzau, G. Paroni, R. Maestro, C. Schneider, and C. Brancolini. 2003. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J. Biol. Chem. 278:12579–12589.
   PubMed Web of Science ®Google Scholar
• Herold, C., M. Ganslmayer, M. Ocker, M. Hermann, A. Geerts, E. G. Hahn, and D. Schuppan. 2002. The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J. Hepatol. 36:233–240.
   PubMed Web of Science ®Google Scholar
• Hockenberry, D., G. Nunez, C. Milliman, R. D. Schreiber, and S. J. Korsmeyer. 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334–336.
   PubMed Web of Science ®Google Scholar
• Ji, L., E. Mochon, M. Arcinas, and L. M. Boxer. 1996. CREB proteins function as positive regulators of the translocated bcl-2 allele in t(14;18) lymphomas. J. Biol. Chem. 271:22687–22691.
   PubMed Web of Science ®Google Scholar
• Kanda, K., H.-M. Hu, L. Zhang, J. Grandchamps, and L. M. Boxer. 2000. NF-κB activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer. J. Biol. Chem. 275:32338–32346.
   PubMed Web of Science ®Google Scholar
• Kiernan, R., V. Bres, R. Ng, W. M. P. Coudart, S. El-Messaoudi, C. Sardet, D. Y. Jin, S. Emiliani, and M. Benkirane. 2003. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2758–2766.
   PubMed Web of Science ®Google Scholar
• Kim, M. S., H. J. Kwon, Y. M. Lee, J. H. Baek, J. E. Jang, S. W. Lee, E. J. Moon, H. S. Kim, S. K. Lee, H. Y. Chung, C. W. Kim, and K. W. Kim. 2001. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7:437–443.
   PubMed Web of Science ®Google Scholar
• Madisen, L., and M. Groudine. 1994. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Genes Dev. 8:2212–2226.
   PubMed Web of Science ®Google Scholar
• Mahlknecht, U., and D. Hoelzer. 2000. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 6:623–644.
   PubMed Web of Science ®Google Scholar
• Marks, P., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly. 2001. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194–202.
   PubMed Web of Science ®Google Scholar
• Marks, P. A., V. M. Richon, and R. A. Rifkind. 2000. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:1210–1216.
   PubMed Web of Science ®Google Scholar
• Martinez-Balbas, M. A., U. M. Bauer, S. J. Nielsen, A. Brehm, and T. Kouzarides. 2000. Regulation of E2F1 activity by acetylation. EMBO J. 19:662–671.
   PubMed Web of Science ®Google Scholar
• Michaelson, J. S., S. L. Giannini, and B. K. Birshtein. 1995. Identification of 3′α-hs4, a novel Ig heavy chain enhancer element regulated at multiple stages of B cell differentiation. Nucleic Acids Res. 23:975–981.
   PubMedGoogle Scholar
• Mills, F., N. Harindranath, M. Mitchell, and E. Max. 1997. Enhancer complexes located downstream of both human immunoglobulin C α genes. J. Exp. Med. 186:845–858.
   PubMed Web of Science ®Google Scholar
• Mitsiades, C. S., N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, C. Bailey, M. Joseph, T. A. Libermann, V. M. Richon, P. A. Marks, and K. C. Anderson. 2004. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA 101:540–545.
   PubMed Web of Science ®Google Scholar
• Nusinzon, I., and C. M. Horvath. 2003. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. USA 100:14742–14747.
   PubMed Web of Science ®Google Scholar
• Pettersson, S., G. P. Cook, M. Bruggemann, G. T. Williams, and M. S. Neuberger. 1990. A second B cell-specific enhancer 3′ of the immunoglobulin heavy chain locus. Nature 344:165–168.
   PubMed Web of Science ®Google Scholar
• Pinaud, E., C. Aupetit, C. Chauveau, and M. Cogne. 1997. Identification of a homolog of the Cα3′/hs3 enhancer and of an allelic variant of the 3′IgH/hs1,2 enhancer downstream of the human immunoglobulin α1 gene. Eur. J. Immunol. 27:2981–2985.
   PubMedGoogle Scholar
• Pogo, B. G., V. G. Allfrey, and A. E. Mirsky. 1966. RNA synthesis and histone acetylation during the course of gene activation in lymphocytes. Proc. Natl. Acad. Sci. USA 55:805–812.
   PubMed Web of Science ®Google Scholar
• Reed, J. C., S. Kitada, S. Takayama, and T. Miyashita. 1994. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann. Oncol. 1(Suppl. 5):S61–S65.
   Google Scholar
• Rosato, R. R., J. A. Almenara, and S. Grant. 2003. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63:3637–3645.
   PubMed Web of Science ®Google Scholar
• Ryu, H., J. Lee, B. A. Olofsson, A. Mwidau, A. Deodoglu, M. Escudero, E. Flemington, J. Azizkhan-Clifford, R. J. Ferrante, and R. R. Ratan. 2003. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. USA 100:4281–4286.
   PubMed Web of Science ®Google Scholar
• Sakai, E., A. Bottaro, and F. W. Alt. 1999. The Ig heavy chain intronic enhancer core region is necessary and sufficient to promote class switch recombination. Int. Immunol. 11:1709–1713.
   PubMedGoogle Scholar
• Saleque, S., M. Singh, R. D. Litter, S. L. Giannini, J. S. Michaelson, and B. K. Birshtein. 1997. Dyad symmetry within the mouse 3′ IgH regulatory region includes two virtually identical enhancers (C alpha3′E and hs3). J. Immunol. 158:4780–4787.
   PubMedGoogle Scholar
• Sambucetti, L. C., D. D. Fischer, S. Zabludoff, P. O. Kwon, H. Chamberlin, N. Trogani, H. Xu, and D. Cohen. 1999. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274:34940–34947.
   PubMed Web of Science ®Google Scholar
• Sawa, H., H. Murakami, Y. Ohshima, T. Sugino, T. Nakajyo, T. Kisanuki, Y. Tamura, A. Satone, W. Ide, I. Hashimoto, and H. Kamada. 2001. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 18:109–114.
   PubMedGoogle Scholar
• Schmitt, C. A., and S. W. Lowe. 2001. Bcl-2 mediates chemoresistance in matched pairs of primary Eμ-myc lymphomas in vivo. Blood Cells Mol. Dis. 27:206–216.
   PubMed Web of Science ®Google Scholar
• Schuettengruber, B., E. Simboeck, H. Khier, and C. Seiser. 2003. Autoregulation of mouse histone deacetylase 1 expression. Mol. Cell. Biol. 23:6993–7004.
   PubMed Web of Science ®Google Scholar
• Seto, M., U. Jaeger, R. D. Hockett, W. Graninger, S. Bennett, P. Goldman, and S. J. Korsmeyer. 1988. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 7:123–131.
   PubMed Web of Science ®Google Scholar
• Suzuki, T., A. Kimura, R. Nagai, and M. Horikoshi. 2000. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells 5:29–41.
   PubMedGoogle Scholar
• Tsujimoto, Y., and C. Croce. 1986. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA 83:5214–5218.
   PubMed Web of Science ®Google Scholar
• Tsujimoto, Y., J. Gorham, J. Cossman, E. Jaffe, and C. M. Croce. 1985. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229:1390–1393.
   PubMed Web of Science ®Google Scholar
• Van Lint, C., S. Emiliani, and E. Verdin. 1996. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp. 5:245–253.
   PubMed Web of Science ®Google Scholar
• Waltzer, L., and M. Bienz. 1998. Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature 395:521–525.
   PubMed Web of Science ®Google Scholar
• Wilson, B. E., E. Mochon, and L. M. Boxer. 1996. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol. Cell. Biol. 16:5546–5556.
   PubMed Web of Science ®Google Scholar
• Wu, Y., J. W. Mehew, C. A. Heckman, M. Arcinas, and L. M. Boxer. 2001. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20:240–251.
   PubMed Web of Science ®Google Scholar
• Xu, M., L. Nie, S.-H. Kim, and X.-H. Sun. 2003. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPβ. EMBO J. 22:893–904.
   PubMed Web of Science ®Google Scholar
• Zhang, W., and J. J. Bieker. 1998. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc. Natl. Acad. Sci. USA 95:9855–9860.
   PubMed Web of Science ®Google Scholar
• Zhang, W. H., R. Srihari, R. N. Day, and F. Schaufele. 2001. CCAAT/enhancer-binding protein alpha alters histone H3 acetylation at large subnuclear domains. J. Biol. Chem. 276:40373–40376.
   PubMedGoogle Scholar
• Zhang, X., W. Wharton, Z. Yuan, S.-C. Tsai, N. Olashaw, and E. Seto. 2004. Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol. Cell. Biol. 24:5106–5118.
   PubMedGoogle Scholar